Accendra Health Names New CEO, Appoints Chief Commercial Officer

What Happened Accendra Health announced on September 17, 2026 that Kenneth Gardner-Smith, a company director since March 2022, will become the Company’s next President and Chief Executive Officer, expected to assume the role early in Q4 2026. He will succeed Edward A. Pesicka, who previously announced his planned retirement and will remain as CEO until the transition and then serve as an advisor. The company also named Scott Lloyd as Chief Commercial Officer, effective October 5, 2026.

Key Details

• Kenneth Gardner-Smith accepted an offer letter dated September 16, 2026: base salary $1,000,000 and target annual cash bonus equal to 130% of base salary (prorated for 2026).
• Long-term incentives for Gardner-Smith: target annual equity award value $6,000,000 (25% RSUs, 25% stock-settled PSUs, 50% cash-settled PSUs).
• One-time sign-on cash bonus $650,000 (payable after six months; subject to repayment if he resigns without Good Reason within 24 months). One-time inducement: cash-settled stock appreciation rights target $2,000,000 (10-year term, vest over 3 years, exercisable after year 3).
• Governance changes: Gardner-Smith will remain on the Board and Executive Committee as a non-independent director and will step down from the Our People & Culture and Audit Committees; those committee seats will be filled by independent directors.
• Scott Lloyd will oversee commercial strategy, sales, and provider/payor partnerships and will report to the CEO; he previously served as Chief Development & Strategy Officer at Evergreen Nephrology and co-founded Extrakare LLC. A press release announcing these appointments was furnished as Exhibit 99.1 to the 8-K.

Why It Matters A formal CEO succession and a dedicated Chief Commercial Officer appointment are material leadership changes. Investors should note the timing of the transition (early Q4 2026), the substantial compensation and incentive package that ties the new CEO’s pay to future performance and retention, and the creation of a focused commercial leadership role aimed at driving growth as Accendra scales its home-based care business. These items can affect strategy execution, governance composition, and near-term cash flow (sign-on and incentive costs), all of which are relevant to shareholders monitoring management stability and growth initiatives.